Works matching IS 00278874 AND DT 2023 AND VI 115 AND IP 9
Results: 14
Reviewers.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 9, p. 1112, doi. 10.1093/jnci/djad157
- Publication type:
- Article
Effect of treatment interruptions on overall survival in patients with triple-negative breast cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 9, p. 1029, doi. 10.1093/jnci/djad127
- By:
- Publication type:
- Article
Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 9, p. 1085, doi. 10.1093/jnci/djad125
- By:
- Publication type:
- Article
Circulating proteome for pulmonary nodule malignancy.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 9, p. 1060, doi. 10.1093/jnci/djad122
- By:
- Publication type:
- Article
Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 9, p. 1099, doi. 10.1093/jnci/djad109
- By:
- Publication type:
- Article
Bilaterality, not multifocality, is an independent risk factor for recurrence in low-risk papillary thyroid cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 9, p. 1071, doi. 10.1093/jnci/djad105
- By:
- Publication type:
- Article
Risk of estrogen receptor–specific breast cancer by family history of estrogen receptor subtypes and other cancers.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 9, p. 1020, doi. 10.1093/jnci/djad104
- By:
- Publication type:
- Article
Seamless phase II/III design: a useful strategy to reduce the sample size for dose optimization.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 9, p. 1092, doi. 10.1093/jnci/djad103
- By:
- Publication type:
- Article
Partial breast irradiation compared with whole breast irradiation: a systematic review and meta-analysis.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 9, p. 1011, doi. 10.1093/jnci/djad100
- By:
- Publication type:
- Article
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 9, p. 1001, doi. 10.1093/jnci/djad096
- By:
- Publication type:
- Article
Interpreting cancer incidence trends: challenges due to the COVID-19 pandemic.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 9, p. 1109, doi. 10.1093/jnci/djad086
- By:
- Publication type:
- Article
Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 9, p. 1077, doi. 10.1093/jnci/djad081
- By:
- Publication type:
- Article
Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 9, p. 1036, doi. 10.1093/jnci/djad080
- By:
- Publication type:
- Article
Lung cancer risk discrimination of prediagnostic proteomics measurements compared with existing prediction tools.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 9, p. 1050, doi. 10.1093/jnci/djad071
- By:
- Publication type:
- Article